Telix Reports Q3 Update, FDA Approves Pixclara and Announces ITM Merger
Telix cited strong U.S. dose volumes, reaffirmed its outlook for over 25% Precision Medicine revenue growth in 2026, received FDA approval for Pixclara and announced a merger with ITM. Figures are unaudited.
Telix reported its Q3 2026 performance, pointing to strong U.S. dose volumes and reaffirming its outlook for Precision Medicine revenue growth of over 25% in 2026. The company also received FDA approval for Pixclara and announced a merger with ITM. The figures are unaudited.